Medication info
Ducaro Tablet 30/5/5 mg (Pimasartan Potassium, Amlodipine, Rosuvastatin)

Ducaro Tablet 30/5/5 mg (Pimasartan Potassium, Amlodipine, Rosuvastatin)

Prescription medicationTabletOral
Ingredient · strength
Fimasartan Potassium Trihydrate Granules›75mg / 1 tabletAmlodipine Besylate›6.94mg / 1 tabletRosuvastatin Calcium Micronized›5.2mg / 1 tablet
Manufacturer / importer
Boryung Pharmaceutical Co., Ltd.
Appearance
White pentagonal film-coated tablet
Packaging
30 tablets/box [10 tablets/PTP*3]
Approval status
Active

MFDS item code 201907894 · Approved 2019.11.13 · Insurance code 641907390

Summary

Main use
Treatment of hypertension and dyslipidemia; reduction of atherosclerosis progression and cardiovascular disease risk
Who takes it
Adults · Children
Adult dose
Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take it at the same time each day (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the fimasartan/amlodipine combination and rosuvastatin. Patients taking the fimasartan/amlodipine combination together with rosuvastatin as a single-ingredient product may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. Fimasartan/Amlodipine Combination Adults Before starting the fimasartan/amlodipine combination, it is recommended that the dose be adjusted using fimasartan. However, if blood pressure is not controlled as described below, switching directly to this medicine may be considered. ㆍ 30/5 mg: For patients whose blood pressure is not adequately controlled with fimasartan 30 mg monotherapy. ㆍ 30/10 mg: For patients whose blood pressure is not adequately controlled with fimasartan 30 mg monotherapy or 30/5 mg. ㆍ 60/5 mg: For patients whose blood pressure is not adequately controlled with fimasartan 60 mg monotherapy. ㆍ 60/10 mg: For patients whose blood pressure is not adequately controlled with fimasartan 60 mg monotherapy or 60/5 mg. Elderly patients No initial dose adjustment is required in elderly patients aged 70 years or younger. In patients aged 75 years or older, amlodipine clearance is reduced; therefore, treatment should be started at a lower dose, and the dose should be increased gradually. Patients with renal impairment No dose adjustment is required in patients with mild or moderate renal impairment (creatinine clearance 30 ~ 80 mL/min). However, in patients with severe renal impairment (creatinine clearance < 30 mL/min), treatment should be initiated with fimasartan 30 mg in this medicine. Patients with hepatic impairment No dose adjustment is required in patients with mild hepatic impairment. This medicine should not be administered to patients with moderate ~ severe hepatic impairment. Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients receiving rosuvastatin should follow a standard cholesterol-lowering diet before and during treatment and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, regardless of meals. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which provides adequate control in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more, according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 mg daily. 2. Elderly patients: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering rosuvastatin 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of rosuvastatin 40 mg is contraindicated in some of these patients.
Child dose
The safety and efficacy of this medicine have not been established in pediatric and adolescent patients aged 18 years or younger.

Ingredients

Manufacturer
Boryung Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension and dyslipidemia; reduction of atherosclerosis progression and cardiovascular disease risk

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • combined dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is a combination of Pimasartan and Amlodipine, used for patients with hypertension whose blood pressure is not adequately controlled by Pimasartan alone. The Rosuvastatin component is used as an adjunctive therapy for patients with hypercholesterolemia and dyslipidemia when diet and exercise alone are insufficient to control lipid levels. It is particularly effective for various lipid disorders, including homozygous familial hypercholesterolemia and primary dysbetalipoproteinemia. Rosuvastatin helps lower total cholesterol and LDL cholesterol levels, delaying the progression of atherosclerosis and reducing the risk of cardiovascular disease. Therefore, this medication is suitable for patients who require simultaneous management of blood pressure and cholesterol, and it is used to improve cardiovascular health.

How to take

Adult dose

Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take it at the same time each day (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the fimasartan/amlodipine combination and rosuvastatin. Patients taking the fimasartan/amlodipine combination together with rosuvastatin as a single-ingredient product may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. Fimasartan/Amlodipine Combination Adults Before starting the fimasartan/amlodipine combination, it is recommended that the dose be adjusted using fimasartan. However, if blood pressure is not controlled as described below, switching directly to this medicine may be considered. ㆍ 30/5 mg: For patients whose blood pressure is not adequately controlled with fimasartan 30 mg monotherapy. ㆍ 30/10 mg: For patients whose blood pressure is not adequately controlled with fimasartan 30 mg monotherapy or 30/5 mg. ㆍ 60/5 mg: For patients whose blood pressure is not adequately controlled with fimasartan 60 mg monotherapy. ㆍ 60/10 mg: For patients whose blood pressure is not adequately controlled with fimasartan 60 mg monotherapy or 60/5 mg. Elderly patients No initial dose adjustment is required in elderly patients aged 70 years or younger. In patients aged 75 years or older, amlodipine clearance is reduced; therefore, treatment should be started at a lower dose, and the dose should be increased gradually. Patients with renal impairment No dose adjustment is required in patients with mild or moderate renal impairment (creatinine clearance 30 ~ 80 mL/min). However, in patients with severe renal impairment (creatinine clearance < 30 mL/min), treatment should be initiated with fimasartan 30 mg in this medicine. Patients with hepatic impairment No dose adjustment is required in patients with mild hepatic impairment. This medicine should not be administered to patients with moderate ~ severe hepatic impairment. Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients receiving rosuvastatin should follow a standard cholesterol-lowering diet before and during treatment and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, regardless of meals. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which provides adequate control in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more, according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 mg daily. 2. Elderly patients: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering rosuvastatin 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of rosuvastatin 40 mg is contraindicated in some of these patients.

Child dose

The safety and efficacy of this medicine have not been established in pediatric and adolescent patients aged 18 years or younger.

Precautions

This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy; therefore, it should be discontinued immediately upon confirmation of pregnancy. Patients with allergies to any of the ingredients, those with severe liver or kidney impairment, pregnant or breastfeeding women, and patients with muscle disorders should not take this medication. Patients with low blood volume or low sodium levels, those with reduced kidney function, elderly patients, and patients with heart disease should exercise particular caution when taking this medication and their condition should be closely monitored. Side effects such as muscle pain, weakness, dizziness, headache, gastrointestinal discomfort, and skin rashes may occur during treatment. If severe muscle-related symptoms arise, immediate consultation with a physician is advised. This medication may interact with other drugs, so anyone taking other medications should inform their healthcare provider, particularly in the case of potassium-sparing diuretics, lithium, non-steroidal anti-inflammatory drugs, certain antibiotics, and antifungals. Women who are pregnant or could become pregnant should use appropriate contraception, and breastfeeding mothers should avoid taking this medication or stop breastfeeding. In case of overdose, symptoms such as hypotension, arrhythmia, and, in severe cases, shock may occur, necessitating immediate medical attention and appropriate treatment based on symptoms. Caution is advised when driving or operating machinery as dizziness may occur during treatment. Safety has not been established in pediatric patients and should be kept out of reach of children during storage.

Side effects

nausea, peripheral edema, nasopharyngitis, influenza, increased serum creatine phosphokinase, dizziness, essential tremor, rash, itching, headache, fainting, sedation, migraine, dyspepsia, vomiting, upper abdominal pain, weakness, foreign body sensation, elevated liver enzymes, decreased platelet count, cough, muscle contractions, musculoskeletal stiffness, facial flushing, erectile dysfunction, facial edema, urination disorder, insomnia, flushing, proteinuria, orthostatic hypotension, headache, dizziness, fainting, sedation, migraine, dyspepsia, vomiting, upper abdominal pain, weakness, foreign body sensation, elevated liver enzymes, decreased platelet count, cough, muscle contractions, musculoskeletal stiffness, itching, localized urticaria, facial flushing, erectile dysfunction, flushing, fatigue, edema, palpitations, vertigo, drowsiness, abdominal pain, nausea, weakness, lethargy, pain, weight gain, weight loss, hypotension, vasculitis, tension increase, sensory decrease, sensory abnormalities, peripheral neuropathy, taste disturbance, tremor, extrapyramidal disorder, erectile dysfunction, gynecomastia, changes in bowel habits, dry mouth, dyspepsia, gastritis, gingival hypertrophy, pancreatitis, vomiting, hyperglycemia, arthralgia, low back pain, muscle cramps, myalgia, leukopenia, thrombocytopenia, insomnia, mood changes, cough, dyspnea, rhinitis, hair loss, hyperhidrosis, purpura, skin discoloration, urticaria, tinnitus, visual disturbances, increased frequency of urination, urination disorder, nocturia, hepatitis, jaundice, elevated liver enzymes, pruritus, rash, angioedema, erythema multiforme, myocardial infarction, arrhythmia, chest pain, hypotension, sinoatrial block, atrioventricular block, abdominal discomfort, retrosternal pain, diarrhea, loose stools, constipation, erythematous urticaria, maculopapular rash, heaviness, warmth sensation, decreased glucose tolerance, weakness, angioedema, hypersensitivity reaction, diabetes, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, dizziness, epilepsy, amyotrophic lateral sclerosis, neuropathy, neuronitis, facial paralysis, normal pressure hydrocephalus, spinal canal stenosis, acute pancreatitis, intestinal obstruction, hemorrhagic duodenal ulcer, appendicitis, hemorrhoids, abdominal pain, intracranial hemorrhage, transient ischemic attack, atherosclerosis, worsening cerebral infarction, cerebral hemorrhage, liver cancer, colon cancer, neoplasm of unspecified nature, cervical cancer, prostate cancer, acute renal failure, chronic renal failure, nephrolithiasis, pyelonephritis, urinary incontinence, rhinitis, interstitial lung disease, pharyngitis, pneumonia, lung disease, death, worsening low back pain, osteoarthritis, arthrosis, hypoglycemia, hyperkalemia, pulmonary embolism, purpura, bradycardia, atrial fibrillation, coronary artery disease, aortic stenosis, heart failure, hypertension, acute hepatitis, benign pituitary neoplasm, otitis media, uterine prolapse, recurrent cancer, chest pain, low back pain, edema, limb pain, neck and shoulder pain, fractures, arthralgia, osteoporosis, myalgia, pharyngitis, upper respiratory infection, sputum, rhinitis, epistaxis, bronchitis, sensory abnormalities, numbness, tremor, spinal canal stenosis, hypertonia, insomnia, depression, anxiety, memory impairment, appetite loss, gastroesophageal reflux, gastritis, diarrhea, constipation, functional dyspepsia, gastroenteritis, frequent urination, urinary incontinence, nephrolithiasis, chronic renal failure, dysuria, hyperlipidemia, dyslipidemia, hypoglycemia, tachycardia, purpura, fatty liver, intestinal vascular edema after angiotensin II receptor antagonist use, Stevens-Johnson syndrome, drug reaction syndrome with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, memory decline, forgetfulness, amnesia, memory impairment, confusion, severe muscle weakness, ocular myasthenia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to protect it from air and moisture, and it is advisable to store it at room temperature between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

White pentagonal film-coated tablet

Package unit

30 tablets/box [10 tablets/PTP*3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.